Enhertu® Shows Significant Progression-Free Survival Benefit in First-Line HER2-Mutant Advanced NSCLC in DESTINY-Lung04 Trial

Enhertu Demonstrates Significant Progression-Free Survival Benefit in First-Line HER2 Mutant Metastatic NSCLC Daiichi Sankyo and AstraZeneca have announced positive topline results from the Phase 3 DESTINY-Lung04 trial, demonstrating that Enhertu®…

Read MoreEnhertu® Shows Significant Progression-Free Survival Benefit in First-Line HER2-Mutant Advanced NSCLC in DESTINY-Lung04 Trial

Clinilabs Expands Leadership Team, Appoints Laura Shannon as CEO and Promotes Founder Gary Zammit, Ph.D. to Executive Chairperson

Clinilabs Expands Leadership Team With Laura Shannon as CEO as Founder Gary Zammit Moves to Executive Chairperson Clinilabs, a specialty contract research organization (CRO) focused on the development of central…

Read MoreClinilabs Expands Leadership Team, Appoints Laura Shannon as CEO and Promotes Founder Gary Zammit, Ph.D. to Executive Chairperson